Objective To compare the differences of biocompatibility and solute removal ability in maintenance hemodialysis (MHD) patients using the dialyzer with cellulose triacetate (CTA) membrane and in those using the dialyzer with polysulfone (PS) membrane. Methods The MHD patients were divided into a PS membrane group and a CTA membrane group according to the clinical responses whether or not they tolerated the PS membrane dialyzer. The effects of the two dialyzers on serum phosphorus (P), blood urea nitrogen (BUN), β2-microglobulin (β2-MG), parathyroid hormone (PTH), complement, IgE, TNF-α, interleukin-6 (IL-6), platelet (PLT), hemoglobin (Hb), calculate urea removal rate (URR) and spKt /V were compared before and after the first dialysis session and after the hemodialysis for 12 months. Results After the first dialysis session, the difference of serum TNF-α was less (Z= -2.491, P=0.013) and the difference of serum β2-MG was more (Z=-2.039, P=0.041) in PS membrane group than in CTA membrane group. After the hemodialysis for 12 months, the differences of P (Z=-2.096, P=0.036), BUN (Z=-2.038, P=0.042), and spKt /V (t =-2.147, P=0.049) were statistically different between the two groups; the difference of P was more in PS membrane group than in CTA membrane group (t =0.114, P=0.041). Conclusions After the first dialysis session, serum TNF-α increased in PS membrane group, suggesting the better biocompatibility of CTA membrane dialyzer; the clearance of β2-MG was better in CTA membrane group than in PS membrane group. After the hemodialysis for 12 months, the biocompatibility became similar in both groups, spKt /V reached the standard level in CTA membrane group, and the clearances of P and BUN were better in CTA membrane group than in PS membrane group.
CHEN Chen
,
ZHANG Chen
,
ZHOU Guang-Yu
,
ZHOU Hua
,
LI De-Tian
,
ZHENG Hua
,
WANG Wen-Qiu
,
WANG Zhe
. A multicenter clinical study of maintenance hemodialysis patients using the dialyzer with cellulose triacetate membrane or polysulfone membrane[J]. Chinese Journal of Blood Purification, 2023
, 22(05)
: 344
-348
.
DOI: 10.3969/j.issn.1671-4091.2023.05.006
[1]. Abe M, Hamano T, Wada A, et al. High-Performance Membrane Dialyzers and Mortality in Hemodialysis Patients: A 2-Year Cohort Study from the Annual Survey of the Japanese Renal Data Registry[J]. Am J Nephrol 2017, 46(1):82-92.
[2]. 罗丽花, 管保章, 闫冰, 等. 血液透析膜材料的研究进展[J]. 临床肾脏病杂志 2015,15(07):440-442.
[3]. 朱冬冬, 刘必成: 透析膜材料的应用进展. 中国血液净化 2014, 13(04):325-328.
[4]. Yamasaki H, Nagake Y, Makino H: Determination of bisphenol a in effluents of hemodialyzers. Nephron 2001, 88(4):376-378.
[5]. Abe T, Kato K, Fujioka T, et al. The blood compatibilities of blood purification membranes and other materials developed in Japan. Int J Biomater 2011, 2011:375390.
[6]. 云扬, 张晨, 刘乃全, 等. 三醋酸纤维素膜与聚砜膜透析器在维持性血液透析患者的临床对照研究. 中国血液净化 2018, 17(08):523-528.
[7]. 栾中佼, 曾维玲, 张晨, 等. 高通量三醋酸纤维素膜与聚砜膜透析器对维持性血液透析患者透析效果的临床研究. 中国实用内科杂志 2020, 40(12):1015-1019.
[8]. Gluba-Brzózka A, Franczyk B, Olszewski R, et al. The Influence of Inflammation on Anemia in CKD Patients. Int J Mol Sci 2020, 21(3).
[9]. Koga Y, Fujieda H, Meguro H, et al. Biocompatibility of Polysulfone Hemodialysis Membranes and Its Mechanisms: Involvement of Fibrinogen and Its Integrin Receptors in Activation of Platelets and Neutrophils. Artif Organs 2018, 42(9):E246-e258.
[10]. Zyga S, Brokalaki H, Virvidakis K, et al. The influence of varying blood and dialysate flow on haemodialysis adequacy. Edtna erca j 2005, 31(1):24-26.
[11]. Claudio-Gonzalez I, Ravindranathan D, Kempton CL, et al. Thrombocytopenia Induced by Polysulfone Dialysis Membranes. Am J Case Rep 2021, 22:e932045.
[12]. Liu S, Shi W, Liang X, et al. Cellulose triacetate dialyzer reduces platelet loss during continuous veno-venous hemofiltration. Blood Purif 2010, 29(4):375-382.
[13]. De Prada L, Lee J, Gillespie A, et al. Thrombocytopenia associated with one type of polysulfone hemodialysis membrane: a report of 5 cases. Am J Kidney Dis 2013, 61(1):131-133.
[14]. Kuragano T, Kuno T, Takahashi Y, et al. Comparison of the effects of cellulose triacetate and polysulfone membrane on GPIIb/IIIa and platelet activation. Blood Purif 2003, 21(2):176-182.
[15]. de Borst MH: The Complement System in Hemodialysis Patients: Getting to the Heart of the Matter. Nephron 2016, 132(1):1-4.
[16]. Ekdahl KN, Lambris JD, Elwing H, et al. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv Drug Deliv Rev 2011, 63(12):1042-1050.
[17]. Mizobuchi M, Towler D, Slatopolsky E: Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009, 20(7):1453-1464.
[18]. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006, 47(5 Suppl 3):S11-145.
[19]. Walker RJ, Sutherland WH, De Jong SA: Effect of changing from a cellulose acetate to a polysulphone dialysis membrane on protein oxidation and inflammation markers. Clin Nephrol 2004, 61(3):198-206.
[20]. 曾维玲, 栾中佼, 周光宇: 透析器过敏反应18例临床分析及文献复习. 中国血液净化 2020, 19(08):521-524.
[21]. Konishi S, Fukunaga A, Yamashita H, et al. Eluted substances from hemodialysis membranes elicit positive skin prick tests in bioincompatible patients. Artif Organs 2015, 39(4):343-351.
[22]. Martin-Navarro J, Esteras R, Castillo E, et al. Reactions to Synthetic Membranes Dialyzers: Is there an Increase in Incidence? Kidney Blood Press Res 2019, 44(5):907-914.
[23]. Tiong MK, Ullah S, McDonald SP, et al. Serum phosphate and mortality in incident dialysis patients in Australia and New Zealand. Nephrology (Carlton) 2021, 26(10):814-823.
[24]. Owen WF, Jr., Lew NL, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993, 329(14):1001-1006.
[25]. Gotch FA, Levin NW, Port FK, et al. Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean. Am J Kidney Dis 1997, 30(1):1-15.
[26]. Cheung AK, Greene T, Leypoldt JK, et al. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008, 3(1):69-77.
[27]. Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006, 17(2):546-555.
[28]. 程海涛, 张晓暄, 李银辉: 肾性骨病发病机制研究及进展. 中国骨质疏松杂志 2020, 26(10):1550-1554.
[29]. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008, 73(11):1296-1302.
